1. Market Research
  2. > Biotechnology
  3. > Genomics Market Trends
  4. > World Cardiac Biomarkers - Market Opportunities and Forecasts, 2014 -2020

The prevention of cardiac diseases by monitoring the heart conditions via cardiac biomarker testing is the profound approach for obtaining rapid results for immediate diagnosing and treatment. Cardiac biomarkers are protein-based traceable substances used as an indicator of biologic state and used for diagnostic and prognostic purposes associated with heart. Cardiac biomarkers are used as risk stratification for various cardiovascular diseases (CVDs), which include myocardial infraction, congestive heart failure, acute coronary syndrome (ACS) among others. The cardiac biomarkers that are widely used as an integrated diagnostic approach for CVDs include CK-MB, troponin I and T, myoglobin, BNPs, IMA and few others. Ability of cardiac biomarkers for accurate and rapid prediction of heart failure after the onset of chest pain has added boost to the market growth. In addition, promising features such as high accuracy, quick outcomes and economic pricing of cardiac point of care (POC) testing is driving the growth of cardiac biomarker market, globally. To keep the momentum of cardiac biomarker, the key manufacturers offers customized solutions. The commercial application of multi-menu options for cardiac testing using different combinations of cardiac biomarkers and target-oriented solutions are the key opportunities of the cardiac biomarker market. However, limited specificity in some cases and side effects such as skeletal muscle injury are some of the factors restraining the growth cardiac biomarkers markets.The Global cardiac biomarker market is segmented based on type, application, location of testing and geography. Based on cardiac biomarker type, the market is segmented into Creatine Kinase (CK-MB), Troponins T and I, myoglobin, BNPs, IMA and others. Troponins I and T are the highest revenue-generating segment in the overall cardiac biomarker market due to its prodigious specificity and its ability to accurately detect the cardiac events of Acute Coronary Syndrome (ACS).Based on application, the market is segmented into myocardial infarction, congestive heart failure, Acute Coronary Syndrome, atherosclerosis and others. Myocardial infarction (MI) holds the highest market share in the global cardiac biomarker market followed by Acute Coronary Syndrome (ACS) due to the highest prevalence rate among cardiovascular diseases (CVDs). The location of testing segment is classified as point of care testing and laboratory testing. Doctors and clinicians largely prefer point of care cardiac testing for quick monitoring patients with chest pain in an emergency care unit, therefore, accounting the fastest CAGR. However, laboratory testing is generating larger revenue in comparison to point of care testing.Based on geography, the global cardiac biomarker market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America leads the global cardiac biomarker market, owing to the high demand for cardiac testing, high CVD prevalence rate and growing awareness towards cardiac diagnostics solutions. Asia-Pacific is growing at the fastest CAGR due to the modernization, increasing disposable incomes and rising affordability for the advanced cardiac treatments.Key companies profiled in this market include Roche Diagnostics, Abbott Laboratories, Siemens Healthcare, Alere Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, BioMerieux, Randox laboratories, Beckman Coulter and Thermo Fisher Scientific. Product launch and technological advancements are the few strategies adopted by the key players of global cardiac biomarker market. The companies are currently focusing on innovative technologies such as automated, multi-assay using combinations of cardiac biomarkers and point-of-care cardiac biomarker devices.

KEY BENEFITS
:Extensive coverage of the global cardiac biomarker market including drivers, restraints and opportunities would help professionals to better understand the market behaviourCountry level analysis has been done to provide micro market sizing of cardiac biomarker in different regionsThe market estimations are made in the report by conducting high-end analysis of the key market segments for the period of 2014-2020A comprehensive analysis of the market scenario in terms of types, applications, location of testing and geography helps identify the growth opportunities in the global cardiac biomarker market The market attractiveness analysis for the Global cardiac biomarker market provides strategic assistance to the decision makersKey market players within the global cardiac biomarker market are profiled in the report and their strategies are analysed thoroughly, which helps in understanding competitive outlook of this market 

KEY MARKET SEGMENTS
:Global Cardiac biomarker market is segmented into type, application, location of testing and geography.Global Cardiac Biomarker Market ‐ By TypeMyocardial muscle Creatine Kinase (CK-MB)Troponins (T and I)MyoglobinBrain Natriuretic Peptide (BNPs) or NT-proBNPIschemia Modified Albumin (IMA)OthersGlobal Cardiac Biomarker Market ‐ By ApplicationMyocardial InfarctionCongestive Heart FailureAcute Coronary SyndromeAtherosclerosisOthersGlobal Cardiac Biomarker Market ‐ By Location of testingPoint of care testingLaboratory testingGlobal Cardiac Biomarker Market ‐ By GeographyNorth AmericaU.S.CanadaMexicoEuropeFranceGermanyU.K.Asia-PacificJapanIndiaChinaAustraliaOthersLAMEALatin AmericaMiddle EastAfrica

Table Of Contents

World Cardiac Biomarkers - Market Opportunities and Forecasts, 2014 -2020
TABLE OF CONTENTSCHAPTER 1 INTRODUCTION1.1 Report description1.2 Key Benefits1.3 Key market segments1.4 Research methodology1.4.1 Secondary research1.4.2 Primary research1.4.3 Analyst tools and modelsCHAPTER 2 EXECUTIVE SUMMARY2.1 CXO perspective2.2 Market beyond what to expect by 2025 ($Million)2.2.1 Moderate growth scenario2.2.2 Rapid growth scenario2.2.3 Diminishing growth scenarioCHAPTER 3 MARKET OVERVIEW3.1 Market Definition and Scope3.2 Biomarker diagnosis vs. conventional diagnosis3.3 Assessment of key advantages and buying criteria for diagnostic biomarkers3.3.1 Early diagnosis3.3.2 Tissue specific diagnosis3.3.3 Reduce clinical trials3.3.4 Risk assessments3.3.5 Consistent output3.4 Key trends impacting the Cardiac biomarker market3.4.1 Development of high sensitive biomarkers for risk stratification3.4.2 Technological advancements in the cardiac biomarkers: Serum based biomarkers3.4.3 Increasing demand for point of care cardiac diagnostics3.5 Key Findings3.5.1 Top Factors Impacting3.5.2 Top Investment Pockets3.5.3 Top winning strategies3.6 Government Regulations and reimbursement3.7 Reimbursement scenario3.8 Porters five force Analysis3.8.1 Bargaining power of suppliers3.8.2 Bargaining power of buyers3.8.3 Threats from substitute products3.8.4 Threat from new entrants3.8.5 Industry rivalry3.9 Value chain analysis3.10 Clinical Trials3.11 Patent Analysis3.12 Market Share Analysis, 20143.13 Market Dynamics3.13.1 Drivers3.13.1.1 Increasing prevalence of cardiovascular diseases3.13.1.2 Cost effective3.13.1.3 Non-invasive3.13.1.4 Accuracy prediction3.13.1.5 Assistant in clinical trials3.13.1.6 Multi-marker application3.13.1.7 Technological advancements using cardiac biomarkers combinations3.13.1.8 Increasing point of care (POC) testing3.13.2 Restraints3.13.2.1 Government Regulation3.13.2.2 Conformation in result3.13.2.3 Complex process3.13.3 Opportunities3.13.3.1 Personalized medicine3.13.3.2 Point of care (POCT) testing using cardiac biomarkers3.13.3.3 Future DEVELOPMENTS IN novel cardiac biomarkersCHAPTER 4 GLOBAL CARDIAC BIOMARKERS MARKET BY TYPE, 2014-20204.1.1 Introduction4.1.2 Key market trends4.1.3 Key growth factors and opportunities4.1.3.1 Characteristics of cardiac biomarkers include:4.1.4 Market size and forecast4.2 Creatine Kinase (CK-MB)4.2.1 Key market trends4.2.2 Key growth factors and opportunities4.2.3 Market size and forecast4.3 Troponins(T,I)4.3.1 Key market trends4.3.2 Key growth factors and opportunities4.3.3 Market size and forecast4.4 Myoglobin4.4.1 Key market trends4.4.2 Key growth factors and opportunities4.4.3 Market size and forecast4.5 Natriuretic peptides (BNP and NT-proBNP)4.5.1 Key market trends4.5.2 Key growth factors and opportunities4.5.3 Market size and forecast4.6 Ischemia Modified Albumin4.6.1 Key market trends4.6.2 Key growth factors and opportunities4.6.3 Market size and forecast4.7 Others4.7.1 Key market trends4.7.2 Key growth factors and opportunities4.7.3 Market size and forecastCHAPTER 5 GLOBAL CARDIAC BIOMARKERS MARKET BY APPLICATION, 2014-20205.1 Myocardial Infarction5.1.1 Market size and forecast5.2 Congestive Heart Failure5.2.1 Market size and forecast5.3 Acute Coronary Syndrome5.3.1 Market size and forecast5.4 Atherosclerosis5.4.1 Market size and forecast5.5 Others5.5.1 Market size and forecastCHAPTER 6 GLOBAL CARDIAC BIOMARKERS MARKET BY LOCATION OF TESTING, 2014-20206.1 Point of care testing6.1.1 Market size and forecast6.2 Laboratory testing6.2.1 Market size and forecastCHAPTER 7 GLOBAL CARDIAC BIOMARKER MARKET BY GEOGRAPHY, 2014-20207.1 North America7.1.1 Key market trends7.1.2 Key growth factors and opportunities7.1.3 Market size and forecast7.1.4 United States7.1.5 Canada7.1.6 Mexico7.2 Europe7.2.1 Key market trends7.2.2 Key growth factors and opportunities7.2.3 Market size and forecast7.2.4 United Kingdom7.2.5 France7.2.6 Germany7.2.7 Others7.3 Asia-Pacific7.3.1 Key market trends7.3.2 Key growth factors and opportunities7.3.3 Market size and forecast7.3.4 China7.3.5 India7.3.6 Australia7.3.7 Japan7.3.8 Rest of Asia Pacific Countries7.4 LAMEA7.4.1 Key market trends7.4.2 Key growth factors and opportunities7.4.3 Market size and forecast7.4.4 Latin America7.4.5 Middle East7.4.6 AfricaCHAPTER 8 COMPANY PROFILES8.1 Abbott laboratories8.1.1 Company Overview8.1.2 Company snapshot8.1.3 Financial performance8.1.4 Operating segment overview8.1.5 Strategic moves and developments8.1.6 SWOT analysis of Abbott Laboratories8.2 Alere Inc.8.2.1 Company overview8.2.2 Alere Inc. snapshot8.2.3 Operating business segments8.2.4 Business performance8.2.5 Key Strategies and developments8.2.6 SWOT analysis of Alere Inc.8.3 Siemens Healthcare8.3.1 Company overview8.3.2 Company snapshot8.3.3 Financial performance8.3.4 SWOT analysis of Siemens Healthcare8.4 Roche Diagnostics Corporation8.4.1 Company overview8.4.2 Roche Diagnostics snapshot8.4.3 Operating business segments8.4.4 Financial performance8.4.5 Strategic moves and developments8.4.6 SWOT analysis Roche Diagnostics8.5 Beckman Coulter8.5.1 Company overview8.5.2 Company Snapshot8.5.3 Strategies and Development8.5.4 Swot Analysis of Beckman Coulter, Inc.8.6 Becton, Dickinson And Co.8.6.1 Company overview8.6.2 Becton Dickinson and Company snapshot8.6.3 Operating Business Segments8.6.4 Business performance8.6.5 Key Strategies and development8.6.6 SWOT analysis of Becton Dickinson and Company8.7 Thermo Fisher Scientific8.7.1 Company profile8.7.2 Company snapshot8.7.3 Business performance8.7.4 Strategic moves and developments8.7.5 SWOT analysis andamp; strategic conclusions8.8 BioMerieux8.8.1 Company overview8.8.2 BioMerieux snapshot8.8.3 Business performance8.8.4 Operating business segments8.8.5 SWOT analysis of BioMerieux8.9 Bio-Rad Laboratories8.9.1 Company profile8.9.2 Company snapshot8.9.3 Business performance8.9.4 Strategic moves and developments8.9.5 SWOT analysis andamp; strategic conclusions8.10 Randox laboratories8.10.1 Company overview8.10.2 Randox Laboratories. snapshot8.10.1 Strategic moves and developments8.10.2 SWOT analysis of Randox LaboratoriesLIST OF FIGURESFIG. 1 IMPACT ANALYSIS OF MODERATE GROWTH SCENARIO (2020-2025)FIG. 2 IMPACT ANALYSIS OF RAPID GROWTH SCENARIO (2020-2025)FIG. 3 IMPACT ANALYSIS OF DIMINISHING GROWTH SCENARIO (2020-2025)FIG. 4 TOP IMPACTING FACTORS FOR CARDIAC BIOMARKER MARKET 2014-2020FIG. 5 TOP INVESTMENT POCKETS OF GLOBAL CARDIAC BIOMARKERS MARKETFIG. 6 TOP WINNING STRATEGIES IN GLOBAL CARDIAC BIOMARKERS MARKET 20112014FIG. 7 PORTERS FIVE FORCES MODELFIG. 8 VALUE CHAINFIG. 9 PATENT ANALYSIS BY GEOGRAPHY (20122015)FIG. 10 MARKET SHARE ANALYSIS, 2014)FIG. 11 SCHEMATIC REPRESENTATION OF CARDIOVASCULAR EVENTS AND RESPECTIVE CARDIAC BIOMARKERS USED FOR DIAGNOSIS AND PROGNOSISFIG. 12 REVENUE GENERATED BY ABBOTT LABORATORIES. (2012-2014)FIG. 13 ABBOTT LABORATORIES, INC. FINANCIAL REVENUES BY BUSINESS UNITSFIG. 14 ABBOTT LABORATORIES, INC. FINANCIAL REVENUES BY GEOGRAPHY (2014)FIG. 15 SWOT ANALYSIS OF ABBOTT LABORATORIES INC.FIG. 16 KEY FINANCIALS OF ALERE INC. BY OPERATING SEGMENTS (2013)FIG. 17 KEY FINANCIALS OF ALERE INC. BY GEOGRAPHY (2013)FIG. 18 KEY FINANCIALS OF ALERE INC. BY THERAPEUTIC AREA (2013)FIG. 19 SWOT ANALYSIS OF ALERE INC.FIG. 20 KEY FINANCIALS OF SIEMENS HEALTHCARE REVENUE, 2011-2014, $MILLIONFIG. 21 KEY FINANCIALS OF SIEMENS HEALTHCARE REVENUES BY SEGMENT 2014FIG. 22 KEY FINANCIALS OF SIEMENS HEALTHCARE REVENUES BY GEOGRAPHY 2014FIG. 23 SWOT ANALYSIS OF SIEMENS HEALTHCAREFIG. 24 KEY FINANCIALS OF ROCHE DIAGNOSTICS BY GEOGRAPHY (2013)FIG. 25 SWOT ANALYSIS OF ROCHE DIAGNOSTICSFIG. 26 KEY FINANCIALS OF BECTON DICKINSON AND COMPANY BY SEGMENT (2013)FIG. 27 KEY FINANCIALS OF BECTON DICKINSON AND COMPANY BY GEOGRAPHY (2013)FIG. 28 SWOT ANALYSIS OF BECTON DICKINSON AND COMPANYFIG. 29 THERMO FISHER SCIENTIFIC INC. FINANCIAL REVENUES BY BUSINESS UNITS (2012)FIG. 30 THERMO FISHER SCIENTIFIC INC. FINANCIAL REVENUES BY GEOGRAPHIC AREAS (2012)FIG. 31 SWOT ANALYSIS OF THERMO FISHER SCIENTIFIC INC.FIG. 32 KEY FINANCIALS OF BIOMERIEUX BY APPLICATIONS (2014)FIG. 33 KEY FINANCIALS OF BIOMERIEUX BY GEOGRAPHY (2014)FIG. 34 SWOT ANALYSIS OF BIOMERIEUXFIG. 35 KEY FINANCIALS OF BIO-RAD LABORATORIES REVENUE, 2012-2014, $MILLIONFIG. 36 BIO-RAD LABORATORIES FINANCIAL REVENUES BY BUSINESS UNITS (2014)FIG. 37 BIO-RAD LABORATORIES FINANCIAL REVENUES BY GEOGRAPHY (2014)FIG. 38 SWOT ANALYSIS OF BIO-RAD LABORATORIESFIG. 39 SWOT ANALYSIS OF RANDOX LABORATORIESLIST OF TABLESTABLE 1 GLOBAL CARDIAC BIOMARKER MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)TABLE 2 MODERATE GROWTH RATE SCENARIO OF CARDIAC BIOMARKER MARKET, 20202025 ($MILLION)TABLE 3 RAPID GROWTH RATE SCENARIO OF CARDIAC BIOMARKER MARKET, 20202025 ($MILLION)TABLE 4 DIMINISHING GROWTH RATE SCENARIO OF CARDIAC BIOMARKER MARKET, 20202025 ($MILLION)TABLE 5 CONVENTIONAL DIAGNOSTICS VERSUS DIAGNOSTIC BIOMARKER TECHNIQUESTABLE 6 TOP WINNING STRATEGIESTABLE 7 CARDIAC BIOMARKERS CURRENTLY IN USETABLE 8 CHARACTERISTICS OF CARDIAC BIOMARKERTABLE 9 GLOBAL CARDIAC BIOMARKER MARKET BY TYPE, 2014 - 2020 ($MILLION)TABLE 10 GLOBAL CARDIAC BIOMARKER CREATINE KINASE MARKET BY GEOGRAPHY, 2014 - 2020 ($MILLION)TABLE 11 GLOBAL CARDIAC BIOMARKER TROPONINS (T,I) MARKET BY GEOGRAPHY, 2014 - 2020 ($MILLION)TABLE 12 GLOBAL CARDIAC BIOMARKER MYOGLOBIN MARKET BY GEOGRAPHY, 2014 - 2020 ($MILLION)TABLE 13 GLOBAL CARDIAC BIOMARKER NATRIURETIC PEPTIDE (BNP AND NT-PROBNP) MARKET BY GEOGRAPHY, 2014 - 2020 ($MILLION)TABLE 14 GLOBAL CARDIAC BIOMARKER ISCHEMIA MODIFIED ALBUMIN MARKET BY GEOGRAPHY, 2014 - 2020 ($MILLION)TABLE 15 GLOBAL CARDIAC BIOMARKER OTHER TYPES MARKET BY GEOGRAPHY, 2014 - 2020 ($MILLION)TABLE 16 GLOBAL CARDIAC BIOMARKER MARKET BY APPLICATIONS, 2014-2020 ($MILLION)TABLE 17 CARDIAC BIOMARKERS USED FOR MONITORING PATIENTS WITH MYOCARDIAL INFRACTIONSTABLE 18 GLOBAL CARDIAC BIOMARKER MYOCARDIAL INFARCTION APPLICATION MARKET BY GEOGRAPHY, 2014 - 2020 ($MILLION)TABLE 19 GLOBAL CARDIAC BIOMARKER CONGESTIVE HEART FAILURE APPLICATION MARKET BY GEOGRAPHY, 2014 - 2020 ($MILLION)TABLE 20 GLOBAL CARDIAC BIOMARKER ACUTE CORONARY SYNDROME APPLICATION MARKET BY GEOGRAPHY, 2014 - 2020 ($MILLION)TABLE 21 GLOBAL CARDIAC BIOMARKER ATHEROSCLEROSIS APPLICATION MARKET BY GEOGRAPHY, 2014 - 2020 ($MILLION)TABLE 22 GLOBAL CARDIAC BIOMARKER OTHERS APPLICATION MARKET BY GEOGRAPHY, 2014 - 2020 ($MILLION)TABLE 23 GLOBAL CARDIAC BIOMARKER MARKET BY LOCATION OF TESTING, 2014-2020 ($MILLION)TABLE 24 GLOBAL CARDIAC BIOMARKER POINT OF CARE TESTING MARKET BY GEOGRAPHY, 2014-2020 ($MILLION)TABLE 25 GLOBAL CARDIAC BIOMARKER LABORATORY TESTING MARKET BY GEOGRAPHY, 2014-2020 ($MILLION)TABLE 26 GLOBAL CARDIAC BIOMARKER MARKET BY GEOGRAPHY, 2014 2020 ($MILLION)TABLE 27 NORTH AMERICA CARDIAC BIOMARKER MARKET BY COUNTRY, 2014 2020 ($MILLION)TABLE 28 UNITED STATES CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 ($MILLION)TABLE 29 CANADA CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 ($MILLION)TABLE 30 MEXICO CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 ($MILLION)TABLE 31 EUROPE CARDIAC BIOMARKER MARKET BY COUNTRY, 2014 2020 ($MILLION)TABLE 32 UNITED KINGDOM CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 ($MILLION)TABLE 33 FRANCE CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 ($MILLION)TABLE 34 GERMANY CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 ($MILLION)TABLE 35 OTHER EUROPE CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 ($MILLION)TABLE 36 ASIA-PACIFIC CARDIAC BIOMARKER MARKET BY COUNTRY, 2014 2020 ($MILLION)TABLE 37 CHINA CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 ($MILLION)TABLE 38 INDIA CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 ($MILLION)TABLE 39 AUSTRALIA CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 ($MILLION)TABLE 40 JAPAN CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 ($MILLION)TABLE 41 OTHER ASIA-PACIFIC CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 ($MILLION)TABLE 42 LAMEA CARDIAC BIOMARKER MARKET BY COUNTRY, 2014 2020 ($MILLION)TABLE 43 LATIN AMERICA CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 ($MILLION)TABLE 44 MIDDLE EAST CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 ($MILLION)TABLE 45 AFRICA CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 ($MILLION)TABLE 46 ABBOTT LABORATORIES BUSINESS SNAPSHOTTABLE 47 ABBOTT LABORATORIES OPERATING SEGEMENTSTABLE 48 ALERE INC. COMPANY SNAPSHOTTABLE 49 ALERE INC. OPERATING SEGEMENTSTABLE 50 COMPANY SNAPSHOT OF SIEMENS HEALTHCARETABLE 51 COMPANY SNAPSHOT OF ROCHE DIAGNOSTICSTABLE 52 ROCHE DIAGNOSTICS OPERATING SEGEMENTSTABLE 53 SNAPSHOT OF BECKMAN COULTER, INCTABLE 54 SWOT ANALYSIS OF BECKMAN COULTER, INCTABLE 55 BECTON DICKINSON AND COMPANY SNAPSHOTTABLE 56 BECTON DICKINSON AND COMPANY OPERATING SEGEMENTSTABLE 57 THERMO FISHER SCIENTIFIC INC. BUSINESS SNAPSHOTTABLE 58 BIOMERIEUX COMPANY SNAPSHOTTABLE 59 BIOMERIEUX OPERATING SEGEMENTSTABLE 60 BIO-RAD LABORATORIES BUSINESS SNAPSHOTTABLE 61 RANDOX LABORATORIES COMPANY SNAPSHOT

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Biobanking: Technologies and Global Markets

Biobanking: Technologies and Global Markets

  • $ 6650
  • Industry report
  • November 2016
  • by BCC Research

Use this report to: - Analyze the role biobanks play in the development of new drugs for specific disease treatments. - Learn about the prevailing market size for certain biobank services available ...

Cardiac Biomarkers Market By Type, By Application, By End Use, By Region And Segment Forecasts to 2024

Cardiac Biomarkers Market By Type, By Application, By End Use, By Region And Segment Forecasts to 2024

  • $ 4950
  • Industry report
  • September 2016
  • by Grand View Research

The cardiac biomarkers market is expected to reach USD13.3 billion by 2024, according to a new report by Grand View Research, Inc. The cardiac biomarkers market is anticipated to witness a lucrative growth ...

Cancer Biomarkers - Global Market Outlook (2016-2022)

Cancer Biomarkers - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • October 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Cancer Biomarkers market is estimated at $9215.32 million in 2015 and is expected to reach $20958.63 million by 2022 growing at a CAGR of 12.5% from 2015 to 2022. ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.